MLL Rearrangement clinical trials at UCSF
1 research study open to eligible people
An MLL rearrangement is when the MLL gene gets mixed up and can trigger leukemia. UCSF is running studies of ziftomenib combined with standard therapy for relapsed or refractory AML. UCSF is collecting safety data and seeing whether leukemia cells shrink after treatment.
Showing trials for
Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
open to eligible people ages 18 years and up
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
San Francisco, California and other locations
Last updated: